前列地尔治疗糖尿病肾病蛋白尿的效果评价

Evaluation of the Effect of Alprostadil on Proteinuria in Diabetic Nephropathy

目的观察前列地尔治疗糖尿病肾病蛋白尿的效果。方法选择该院2015年8月—2016年8月收治的糖尿病肾病患者66例,随机将其分为两组,即对照组(33例)和观察组(33例),两组患者均给予常规治疗和贝那普利治疗,观察组在此基础上给予前列地尔治疗,对比两组患者疗效及治疗前后蛋白尿水平。结果治疗后,相较于对照组,观察组患者治疗总有效率明显升高,差异有统计学意义(P<0.05),两组患者24 h尿蛋白含量和尿微量白蛋白较治疗前均有所降低,且观察组降低程度明显优于对照组,差异有统计学意义(P<0.05)。结论前列地尔治疗糖尿病肾病蛋白尿疗效显著,建议在临床上推广应用。

Objective This p ap er tries to evaluate the effect of alprostadil on proteinuria in diabet ic nephropathy. Methods 66 cases of patients with diabetic nephropathy from August 2015 to August 2016 were chosen and randomly divided into the control group and the observation group, with 33 cases in each group. Both groups were given routine treatment and benazepril treatment, the observation group added alprostadil treatment, and the curative efficacy and proteinuria levels of both groups before and after treatment were compared. Results Compared with the control group, the total effective rate of the observation group significantly increased （P〈0.05）. The 24 h urinary protein content and urinary albumin after treatment in the two groups were lower than those before, and that of the observation group was significantly better than the control group （P〈0.05）. Conclusion Curative effect of alprostadil treatment on proteinuria in diabet ic nephropathy is remarkable, so it is worth clinical application.